ProSomnus, Inc. (OSA)
Stock analysis · NASDAQ · Healthcare · Medical - Devices
$0.47
Market Cap
$8.18M
PE (TTM)
-0.32
EPS (TTM)
N/A
Dividend Yield
0.00%
Beta
0.21
Day Range
$0.47 – $0.50
52-wk Range
$0.47 – $0.50
Avg Volume
N/A
Volume
58.85K
ProSomnus, Inc. (OSA) is a publicly traded company in the Healthcare sector. Latest price: $0.47. Market cap $8.18M. Trailing PE -0.32. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Most Recent
Mar 27, 2024
EPS $-0.42 vs est. $-0.31
Missed by $0.11
Proprietary Signals
About ProSomnus, Inc.
ProSomnus, Inc. develops and provides specialized oral appliance therapy solutions crafted to alleviate obstructive sleep apnea (OSA). This enterprise, which originated in 2016, maintains its headquarters in Pleasanton, California.
Valuation
| P/E (TTM) | -0.32× |
|---|---|
| P/S (TTM) | 0.30× |
| P/B | -0.29× |
| PEG | 0.00× |
| P/FCF (TTM) | -0.46× |
| EV / EBITDA | -2.40× |
| EV / Sales | 1.54× |
| Earnings Yield | -316.91% |
| Free Cash Flow Yield | -215.21% |
Fundamentals
| Enterprise Value | $42.48M |
|---|---|
| Revenue (TTM) | $27.65M |
| Net Income (TTM) | -$25.91M |
| Free Cash Flow (TTM) | -$9.74M |
| Net Debt | $34.31M |
| Working Capital | -$31.00K |
| Gross Margin | 50.67% |
| Operating Margin | -69.09% |
| Net Margin | -87.14% |
| Return on Equity | 102.32% |
| Return on Invested Capital | -123.39% |
Peers
Recent News
- Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
- Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adu…
- Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 d…
- Apnimed Announces Pricing of Upsized Initial Public Offering
Related
Browse more tickers: sitemap